[go: up one dir, main page]

AR102872A1 - ANTI-PD-1 ANTIBODIES AND THEIR METHODS OF USE - Google Patents

ANTI-PD-1 ANTIBODIES AND THEIR METHODS OF USE

Info

Publication number
AR102872A1
AR102872A1 ARP150103926A ARP150103926A AR102872A1 AR 102872 A1 AR102872 A1 AR 102872A1 AR P150103926 A ARP150103926 A AR P150103926A AR P150103926 A ARP150103926 A AR P150103926A AR 102872 A1 AR102872 A1 AR 102872A1
Authority
AR
Argentina
Prior art keywords
antibodies
methods
bind
treatments
antibody
Prior art date
Application number
ARP150103926A
Other languages
Spanish (es)
Inventor
Youssef Sawsan
Rajpal Arvind
Ute Jooss Karin
Ho Weihsien
Kim Cho Helen
Noubia Abdiche Yasmina
Original Assignee
Rinat Neuroscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rinat Neuroscience Corp filed Critical Rinat Neuroscience Corp
Publication of AR102872A1 publication Critical patent/AR102872A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Anticuerpos antagonistas que se fijan a la proteína de muerte celular programada 1 (PD-1) y métodos para usarlos. Los anticuerpos anti-PD-1 se pueden usar terapéuticamente solos o en combinación con otros tratamientos para tratar el cáncer y otras enfermedades. Célula huésped, ADN, vector, método para producir el anticuerpo, composición farmacéutica.Antagonist antibodies that bind to programmed cell death protein 1 (PD-1) and methods to use them. Anti-PD-1 antibodies can be used therapeutically alone or in combination with other treatments to treat cancer and other diseases. Host cell, DNA, vector, method for producing the antibody, pharmaceutical composition.

ARP150103926A 2014-12-09 2015-12-01 ANTI-PD-1 ANTIBODIES AND THEIR METHODS OF USE AR102872A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462089658P 2014-12-09 2014-12-09

Publications (1)

Publication Number Publication Date
AR102872A1 true AR102872A1 (en) 2017-03-29

Family

ID=58672231

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103926A AR102872A1 (en) 2014-12-09 2015-12-01 ANTI-PD-1 ANTIBODIES AND THEIR METHODS OF USE

Country Status (1)

Country Link
AR (1) AR102872A1 (en)

Similar Documents

Publication Publication Date Title
CL2019000061A1 (en) Antibody for anti-claudin 18a2 and its use.
MX2017007537A (en) ANTI-PD-1 ANTIBODIES AND THEIR METHODS OF USE.
ECSP19011185A (en) Bispecific antibody-like binding proteins that specifically bind CD3 and CD123
AR115389A1 (en) CD73 ANTAGONIST ANTIBODY
CO2019006485A2 (en) Antibodies and methods of their use
MX2018013548A (en) Bispecific binding proteins and uses thereof.
CL2017002244A1 (en) Specific bispecific antibodies for fap and dr5, specific antibodies for dr5 and methods of use. (divisional application 2829-2015).
AR105444A1 (en) THERAPEUTIC ANTIBODIES THAT JOIN THE PROTEIN CODIFIED BY THE GENOPHYPE ACTIVATION GEN 3 (LAG3)
DOP2018000045A (en) ANTIBODIES PD-L1
AR101845A1 (en) ANTI-HER2 AND IMMUNOCUSED ANTIBODIES
MX2017014955A (en) T-CELL IMMUNORRECEPTOR UNION AGENTS WITH IG DOMAINS AND INHIBITION REASON BASED ON IMMUNORRECEPTOR TIROSINE (TIGIT) AND USES OF THE SAME.
MY195110A (en) Antibodies to PD-1 and uses Thereof
MX2023000818A (en) Anti-ctla-4 antibodies and methods of use thereof.
BR112017008914A2 (en) method for treating cancer, makeup and use of makeup
MX2018000621A (en) ANTI-PD-1 ANTIBODIES, ACTIVABLE ANTI-PD-1 ANTIBODIES, AND METHODS OF USE OF THE SAME.
AR103488A1 (en) ANTI-CD3 ANTIBODIES, ANTI-CD123 ANTIBODIES AND BIESPECIFIC ANTIBODIES THAT SPECIFICALLY JOIN CD3 AND / OR CD123
AR107442A1 (en) ANTIBODIES AGAINST THE ORPHANE RECEPTOR SIMILAR TO THE THIROSINE QUINASE 1 (ANTI-ROR1) RECEPTOR, BISPECIFIC ANTIBODIES THAT JOIN ROR1 AND THE CD3 ANTIGEN, AND METHODS FOR TREATMENT OF CANCER
AR103867A1 (en) ANTIBODIES AGAINST IMMUNOGLOBULIN AND DOMAIN 3 CONTAINING MUCINE OF T-CELLS (ANTI-TIM3), USEFUL AS THERAPEUTIC AGENTS
AR105489A1 (en) PD-1 ANTIBODIES
CR20180065A (en) BIESPECTIFIC ANTIBODY CONSTRUCTS THAT JOIN EGFRVIII AND CD3
CL2019001671A1 (en) Specific antibodies for fcrn (divisional application 201601147)
CL2016002004A1 (en) Anti-jagged1 antibodies and methods of use
UY37279A (en) TGF-BETA ANTIBODIES AND JOINT FRAGMENTS OF THE SAME
BR112017023131A2 (en) anti-fnc antibodies
MX2018016096A (en) ANTI-AXL ANTAGONIST ANTIBODIES.